Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells.

Endocrine - 1 Jan 2023

Jiang Suyuan, Huang Yuxin, Li Yuan, Gu Qin, Jiang Cuiping, Tao Xiaoming, Sun Jiao

Abstract excerpt

BACKGROUND: Vemurafenib (VEM) is a commonly used inhibitor of papillary thyroid cancer (PTC) and melanoma with the BRAFV600E mutation; however, acquired resistance is unavoidable. The present study aimed to identify a potential target to reverse resistance. MATERIALS AND METHODS: A VEM-resistant PTC cell line (B-CPAP/VR) was established by gradually increasing the drug concentration, and a VEM-resistant BRAFV600E...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Forkhead Transcription Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 36331719
DOI: 10.1007/s12020-022-03180-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells.PMID 36331719Read ↗

POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation.Semantic proximity Read ↗

FOXP Transcription Factors in Thyroid Cancer: From Molecular Expression to Clinical SignificanceSemantic proximity Read ↗

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.Semantic proximity Read ↗

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Semantic proximity Read ↗

FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6Semantic proximity Read ↗

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.Semantic proximity Read ↗

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.Semantic proximity Read ↗

The Downregulation of EIF3a Contributes to Vemurafenib Resistance in Melanoma By Activating ERK Via PPP2R1BSemantic proximity Read ↗

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma modelSemantic proximity Read ↗

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.Semantic proximity Read ↗

Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.